Although EPO is accepted as a safe therapeutic for treating anaemia, the clinical use of EPO as a cytoprotective drug raises concerns of its possible adverse side effects, such as thromboembolism and hypertension [15]–[17] because the tissue protective doses of EPO are much higher than those needed for stimulation of haematopoiesis [11]. The gene discussed is EPO; the disease is anemia (phenotype).